17:20:16 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-03-06 Kvartalsrapport 2025-Q2
2024-11-08 Årsstämma 2025
2024-09-20 Bokslutskommuniké 2024
2024-03-07 Kvartalsrapport 2024-Q2
2023-11-17 X-dag ordinarie utdelning HEALTH 0.00 EUR
2023-11-16 Årsstämma 2024
2023-09-28 Bokslutskommuniké 2023
2023-04-24 Extra Bolagsstämma 2023
2023-03-23 Kvartalsrapport 2023-Q2
2022-11-17 Årsstämma 2023
2022-10-25 X-dag ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 Bokslutskommuniké 2022
2022-06-29 Extra Bolagsstämma 2022
2022-02-24 Kvartalsrapport 2022-Q2
2021-10-29 X-dag ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 Årsstämma 2022
2021-09-15 Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.
2024-07-04 13:35:00

Nightingale Health Plc
Managers' Transactions
4 July 2024 14:35 p.m. (EEST)

Person subject to the notification requirement
Name: Cor Group Oy
Position: Closely associated person
(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer
Name: Olli Karhi
Position: Member of the Board
Issuer: Nightingale Health Oyj
LEI: 743700WUIPC24LVMLO66
Notification type: INITIAL NOTIFICATION
Reference number: 69373/7/8

____________________________________________
Transaction date: 2024-07-03
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000490875
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 536842 Unit price: 2 EUR

Aggregated transactions (1):
Volume: 536842 Volume weighted average price: 2 EUR

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified Adviser:
Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world's most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale's Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com